Full green light for Biogen’s MS drug Fampyra
Biogen’s Fampyra has been granted a standard approval by European regulators on the back of late-stage data supporting its use to improve walking in patients with multiple sclerosis.
Read More
Tag: walking
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
